Comparison
BPC-157 vs Bromantane
Side-by-side of BPC-157 and Bromantane. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
Side-by-side
| Attribute | BPC-157 | Bromantane |
|---|---|---|
| Category | peptide | nootropic |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine |
| Half-life (hr) ↗ | 4 | 11 |
| Typical dose (mg) ↗ | 0.25 | 75 |
| Dosing frequency | daily (anecdotal protocols) | daily, morning |
| Routes | subcutaneous, intramuscular, oral | oral |
| Onset (hr) | - | 3 |
| Peak (hr) | - | 168 |
| Molecular weight | - | 280.21 |
| Molecular formula | C62H98N16O22 | C16H20BrN |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK |
| WADA status | banned | banned |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not scheduled in the US |
| Pregnancy | Insufficient data | Not recommended |
| CAS | 137525-51-0 | 87913-26-6 |
| PubChem CID | 9941957 | 9576456 |
| Wikidata | Q4835418 | Q4093816 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
Which Should You Take?
Bromantane comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-C outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick BPC-157.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is focus or working memory, pick Bromantane.
- → If your priority is fatigue resistance, pick Bromantane.
Default choice: Bromantane. Wider use case, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and Bromantane?
BPC-157 and Bromantane differ in category (peptide vs nootropic), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or Bromantane?
BPC-157 half-life is 4 hours; Bromantane half-life is 11 hours.
Can you stack BPC-157 with Bromantane?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper